The hydrazone Schiff base analogues namely benzoic acid (4-allyloxy-benzylidene)-hydrazide and its series were designed and synthesized. The structures of newly synthesized compounds were characterized by analytical methods and spectral analysis and subjected to antibacterial and docking studies. The synthesized molecules were subjected to molecular docking studies using enoyl-acyl-carrier protein reductase (NADH) from mycobacterium tuberculosis as the receptor. The docking results confirm the binding affinity of the synthesized compounds with the selected receptor. Preliminary in-vitro anti bacterial studies were carried out with Gram-positive (Staphylococcus aureus) and Gram-negative (Escherichia coli) bacteria. Benzoic acid (4-allyloxy-benzylidene)-hydrazide was found to be most potent anti tuberculosis agent at 200 and 100µg per ml, the percentage of inhibition was 98.7% and 97.9%. The designed synthesized molecules were considered for evaluation for the molecular docking studies of their binding pattern with enoyl-acyl-carrier protein reductase from Mycobacterium tuberculosis. The antimycobacterial screening was performed against MTB H37Rv an isoniazid-resistant clinical isolate of MTB was used for the study.